Glycine, N-[(2E)-2-methyl-1-oxo-2-butenyl]-

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Glycine, N-[(2E)-2-methyl-1-oxo-2-butenyl]-
• 英文别名: 2-(2-methylbut-2-enoylamino)acetic acid
• 化学式: C₇H₁₁NO₃
• mdl: MFCD30339803
• 分子量: 157.17
• InChiKey: WRUSVQOKJIDBLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] PYRONE COMPOUND AND ITS USE FOR PEST CONTROL<br/>[FR] COMPOSÉ DE PYRONE ET SON UTILISATION POUR LUTTER CONTRE LES ORGANISMES NUISIBLES
  申请人：SUMITOMO CHEMICAL CO

  公开号：WO2011049150A1

  公开（公告）日：2011-04-28

  A pyrone compound represented by formula (1) has an excellent controlling effect on pests. Since the compound of formula (1) has a controlling activity on pests, the compound is useful as an active ingredient of a pest control agent.

  由公式（1）表示的吡喁化合物对害虫有出色的控制效果。由于公式（1）的化合物对害虫具有控制活性，因此该化合物可用作杀虫剂的活性成分。
• METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDS
  申请人：Hitoshi Yasumichi

  公开号：US20150087673A1

  公开（公告）日：2015-03-26

  Disclosed are methods of using AMPK-activating compounds, for example, in the treatment of cancer and disorders of vascular flow. Also disclosed are biomarkers for AMPK and uses thereof, for example, in the diagnosis and treatment of AMPK-linked disorders. In certain embodiments, the AMPK-activating compounds have the structural formula wherein E, J, T, D 1 , D 2 , D 3 , the ring system denoted by “B”, T, R 3 , R 4 , w and x are as described herein.

  本文公开了使用AMPK激活化合物的方法，例如在癌症和血管流动障碍的治疗中的应用。还公开了AMPK的生物标志物及其用途，例如在AMPK相关疾病的诊断和治疗中的应用。在某些实施例中，AMPK激活化合物具有以下结构式，其中E、J、T、D1、D2、D3、由“B”表示的环系统、T、R3、R4、w和x如本文所述。
• METHOD OF DETERMINING TRACE METAL
  申请人：Kowa Co., Ltd.

  公开号：EP1574531A1

  公开（公告）日：2005-09-14

  Provided are a method, upon radical copolymerization of a vinyl-containing porphyrin compound and a radically polymerizable monomer, thereby obtaining a porphyrin-nucleus introduced polymer, of controlling reactivity of the porphyrin-nucleus introduced polymer with a metal by selecting the radically polymerizable monomer; and a method for measuring a trace metal by measuring a change in absorbance caused by complex forming reaction between a porphyrin-nucleus introduced polymer, which has been obtained by radical copolymerization of a vinyl-containing porphyrin compound and a radically polymerizable monomer, and a heavy metal ion, said radically polymerizable monomer being selected so as to heighten reaction selectivity of the porphyrin-nucleus introduced polymer to a metal to be measured. The present invention, by selecting the radically polymerizable monomer as a raw material for the porphyrin-neucleus introduced polymer as a measuring reagent, makes it possible to change the water-solubility or the reactivity of the measuring reagent with the metal in complex formation so that the target metal can be measured highly sensitively and easily.

  提供了一种方法，在含乙烯基的卟啉化合物和可辐射聚合的单体进行自由基共聚，从而获得卟啉核引入聚合物时，通过选择可辐射聚合的单体来控制卟啉核引入聚合物与金属的反应性；以及一种测量痕量金属的方法，该方法通过测量由含乙烯基的卟啉化合物和可辐射聚合单体自由基共聚得到的卟啉核导入聚合物与重金属离子之间的络合物形成反应引起的吸光度变化，所述可辐射聚合单体的选择是为了提高卟啉核导入聚合物对待测金属的反应选择性。 本发明通过选择可辐射聚合的单体作为卟啉-核引入聚合物作为测量试剂的原料，可以改变测量试剂的水溶性或与金属形成络合物的反应性，从而可以高灵敏度、简便地测量目标金属。
• Biomarkers for prostate cancer and methods using the same
  申请人：Metabolon Inc.

  公开号：EP2560006A2

  公开（公告）日：2013-02-20

  Methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early predication of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for prostate cancer

  本研究提供了鉴定和评估可用作前列腺癌早期预测、疾病分级、靶点鉴定/验证和药物疗效监测的生物标记物的生化和/或基因实体组的方法。此外，还提供了作为前列腺癌生物标记物的小分子实体套件。
• Metabolomic profiling of prostate cancer
  申请人：The Regents of the University of Michigan

  公开号：EP2597464A2

  公开（公告）日：2013-05-29

  The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer. The present invention further provides diagnostic, research, and therapeutic applications targeting cancer specific metabolites.

  本发明涉及癌症标记物。特别是，本发明提供了在前列腺癌中不同程度存在的代谢物。本发明进一步提供了针对癌症特定代谢物的诊断、研究和治疗应用。